Prognostic factors in Krukenberg tumor

Arch Gynecol Obstet. 2019 Nov;300(5):1155-1165. doi: 10.1007/s00404-019-05301-x. Epub 2019 Sep 21.

Abstract

Background: Krukenberg tumor (KT) is a rare secondary ovarian tumor. Little is known about clinicopathologic factors affecting prognosis in KT.

Objective: To assess the prognostic value of clinicopathologic factors in KT through a systematic review and meta-analysis.

Methods: Electronic databases were searched from their inception to February 2019 for studies assessing the association of clinicopathologic factors with overall survival in KT. Pooled hazard ratio (HR) was calculated for each factor; a p value < 0.05 was considered significant.

Results: Twenty-three studies with 1743 patients were included. A decreased overall survival was significantly associated with peritoneal involvement (HR 1.944; p = 0.003), ascites (HR 2.055; p = 0.034), synchronous presentation (HR 1.679; p = 0.034) and increased serum CEA levels (HR 1.380; p = 0.010), but not with age > 50 (HR 0.946; p = 0.743), menopausal status (HR 1.565; p = 0.204), gastric origin (HR 1.600; p = 0.201), size > 5 cm (HR 1.292; p = 0.119), size > 10 cm (HR 0.925; p = 0.714), bilateral ovarian involvement (HR 1.113; p = 0.347), non-peritoneal extaovarian metastases (HR 1.648; p = 0.237), liver metastases (HR 1.118, p = 0.555), predominant signet ring cell morphology (HR 1.322; p = 0.208) and levels of CA125 (HR 0.933; p = 0.828) and CA19.9 (HR 0.996; p = 0.992).

Conclusion: Peritoneal involvement, synchronous presentation, ascites and increased serum CEA levels appear as unfavorable prognostic factors in KT and might affect the patient management.

Keywords: Cancer; Hazard ratio; Management; Metastasis; Oncology; Prognosis; Therapy.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Biomarkers, Tumor / blood
  • CA-125 Antigen / blood
  • Female
  • Humans
  • Krukenberg Tumor / pathology*
  • Middle Aged
  • Ovarian Neoplasms / pathology*
  • Prognosis

Substances

  • Biomarkers, Tumor
  • CA-125 Antigen